百里香提取物/常春藤提取物(Thyme Extract/Hedera Extract) - 在研适应症：新型冠状病毒感染，急性支气管炎_专利_临床

概要

基本信息

药物类型

中药

别名

Bronchipret、fixed combination of thyme herb and ivy leaf fluid extracts、Bronchipret

靶点-

作用机制-

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染急性支气管炎

非在研适应症-

原研机构

Bionorica SE

在研机构

Bionorica SE

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与百里香提取物/常春藤提取物相关的临床试验

NCT05276375 / Completed临床2期IIT

Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19 (BroVID)

There is currently an urgent need for effective and safe treatments of Coronavirus Disease (COVID) - 19 and the cytokine storm that is responsible for the development of patient's Acute Respiratory Distress Syndrome (ARDS).
As Bronchipret has been proven to be a very safe medicine, it is not expected that it would lead to the development of severe adverse effects in COVID-19 patients. Bronchipret can therefore be recommended as effective and safe supplementary treatments of COVID-19, even more so considering the positive effects shown in vitro. Thus, this randomized study is conducted to assess the effect of Bronchipret on the immune response and recovery in patients with mild COVID-19 by assessing several blood parameters as well as the symptom recovery and improvement in comparison to patients who do not receive Bronchipret. Another aim of this feasibility study is to determine the best possible primary endpoint, i.e. which shows the greatest effect according to Cohen.

开始日期2022-01-14

申办/合作机构

Fraunhofer Institute For Molecular Biology & Applied Ecology

[+1]

NCT01928901 / Completed临床2期

Randomized, Placebo-controlled, Double-blind, Cross-over Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)

Proof of concept: Superiority of Bronchipret or Sinupret to placebo in respect to mucociliary clearance

开始日期2013-08-01

申办/合作机构

Bionorica SE

EUCTR2006-000330-13-DE / Not yet recruitingN/A

Efficacy and tolerability of Bronchipret® TP film coated tablets for the treatment of acute bronchitis in adults. - acute bronchitis

开始日期2006-09-18

申办/合作机构

Bionorica SE

100 项与百里香提取物/常春藤提取物相关的临床结果

登录后查看更多信息

100 项与百里香提取物/常春藤提取物相关的转化医学

登录后查看更多信息

100 项与百里香提取物/常春藤提取物相关的专利（医药）

登录后查看更多信息

9

项与百里香提取物/常春藤提取物相关的文献（医药）

2021-10-03·Current Medical Research and Opinion4区 · 医学

Effectiveness and tolerability of the thyme/ivy herbal fluid extract BNO 1200 for the treatment of acute cough: an observational pharmacy-based study

4区 · 医学

Article

作者: Abramov-Sommariva, Dimitri ; Birring, Surinder S. ; Kardos, Peter ; Seibel, Jan ; Bittner, Claudia B.

OBJECTIVEEfficacy and safety of an oral thyme/ivy syrup for the treatment of acute cough was previously demonstrated in a randomized clinical trial. Here, we present real-life data from a pharmacy-based, observational study on the effectiveness and tolerability of another thyme/ivy combination (BNO 1200, Bronchipret drops).METHODSThis observational, prospective, uncontrolled study was conducted in 305 German pharmacies. Cough and associated symptoms, cough severity and health related quality of life (HRQoL) were assessed at baseline, after 4 days and at individual end of treatment (EoT) in patients with acute cough due to upper respiratory tract infections who bought BNO 1200. Patients took BNO 1200 until resolution of cough and completed three validated questionnaires: patient-adapted Bronchitis Severity Score (BSS), cough severity visual analogue scale (VAS) and the Leicester Cough Questionnaire (LCQ-acute). They also rated speed of onset of treatment action on a VAS and tolerability.RESULTSA total of 749 patients participated in the study; 730 were included in the analysis. Mean treatment duration was 7.0 ± 3.6 days. Symptom severity assessed by BSS improved from 8.7 ± 3.8 score points (baseline) to 2.4 ± 2.6 at EoT (p < .0001). Clinically relevant improvements (MCID = 17 mm) in cough severity were reported by 87.2% of patients at EoT. HRQoL improved significantly (12.2 ± 3.3 points at baseline vs. 18.5 ± 2.7 at EoT; p < .0001), exceeding the MCID (=2 points) in 90.0% of patients. Tolerability was rated "good" or "very good" by 98.0% of patients. No adverse drug reactions were reported.CONCLUSIONPatients with acute cough taking BNO 1200 had a significant reduction in BSS, cough severity and improvement in HRQoL confirming RCT data with the syrup formulation. BNO 1200 was well tolerated.

2018-08-01·Pulmonary Pharmacology & Therapeutics3区 · 医学

In vivo and in vitro investigation of anti-inflammatory and mucus-regulatory activities of a fixed combination of thyme and primula extracts

3区 · 医学

Article

作者: Lehner, Martin D ; Pongrácz, Judit E ; Seibel, Jan ; Kryshen, Kirill

Hypersecretion of viscous mucus is one of the hallmark symptoms of acute and chronic bronchitis and typically develops secondary to an inflammation of the airway epithelium. Bronchipret^® TP film-coated tablets (BRO), a herbal medicinal product containing a fixed combination of thyme herb and primula root extracts, has been successfully used clinically for the treatment of acute bronchitis for more than two decades. However, the underlying pharmacological mechanisms of action have not been fully understood so far. We investigated the anti-inflammatory and mucus-regulatory effects of orally administered BRO in an animal model of pulmonary inflammation that was experimentally induced by intratracheal LPS instillation. BRO was administered once daily for up to three days following the induction of inflammation. Treatment with BRO effectively inhibited polymorphonuclear cell influx into the lung as well as the increase in mucin 5ac (MUC5AC) protein. Furthermore, the LPS-induced increase of goblet cell numbers was significantly attenuated by BRO treatment. Subsequent in vitro investigations with IL-13 stimulated human primary respiratory epithelium and the Calu-3 respiratory epithelial cell line in air-liquid-interface culture confirmed the effects on mucus production and goblet cell numbers observed in the in vivo studies. They further suggest that the reduction of MUC5AC protein secretion by BRO is associated with reduced MUC5AC mRNA expression as assessed by quantitative Real-Time PCR. Our studies provide evidence that BRO exerts both anti-inflammatory and mucus-regulatory activity and that BRO's effect on mucin production is partially independent from its anti-inflammatory activity. These results contribute to the understanding of the modes of action underlying the clinical efficacy of BRO in acute bronchitis patients.

2017-12-22·Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego

[Bronchipret TE® in therapy of acute infections of the respiratory tract].

Review

作者: Doniec, Zbigniew ; Płusa, Tadeusz ; Mastalerz-Migas, Agnieszka

Bronchipret TE® exhibits multidirectional anti-inflammatory effects as demonstrated in vitro and in vivo studies. It has been disclosed that the drug has the ability to activate the bronchial cleaning mechanism, inhibit the respiratory tract remodeling process by reducing the number of goblet cells, inhibiting enzyme activity and proinflammatory mediators. These mechanisms cause the administration of medication to cause acute bronchitis patients to shorten and alleviate the course of the disease with rapid cough elimination. Use of Bronchipret TE® is in accordance with the recommendations of the European Guideline Committee's and the German Respiratory Society.

100 项与百里香提取物/常春藤提取物相关的药物交易

登录后查看更多信息